Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot
NEW BRUNSWICK, N.J., Nov. 7, 2023 /PRNewswire/ -- Johnson & Johnson MedTech* today announced plans to submit the OTTAVA robotic surgical system for an investigational device exemption (IDE) application to the U.S. Food & Drug Administration (FDA) in the second half of 2024 to initiate clinical trials.
- Drawing on Johnson & Johnson MedTech's more than 135-year legacy of leadership in surgery, OTTAVA reimagines the surgical experience.
- "Johnson & Johnson was born in surgery with the advent of sterile sutures, and we have since helped surgeons improve care for patients by offering transformative technologies across all types of surgery," said Hani Abouhalka, Company Group Chairman, Robotics & Digital, Johnson & Johnson MedTech.
- Ethicon instruments on OTTAVA are backed by decades of innovation and market leadership in minimally invasive surgery, providing leading device-to-tissue and user-to-device interactions.
- The OTTAVA robotic system is under development and is not authorized to be marketed or sold in any market.